开设账户
模拟账户
关于我们
即时报价及新闻
市场分析
财经日历
每日市场分析
交易平台
下载及介绍
使用教学
交易细则
各项细则
资金提存
推广和资讯
常见问题
联络我们
繁
简
EN
客户登入
开设账户
模拟账户
繁
简
EN
客户登入
开设账户
模拟账户
关于我们
上志国际介绍
上志国际优势
即时报价及新闻
即时报价
即时新闻
市场分析
财经日历
市场分析
交易平台
平台特点
平台教学
交易细则
各项细则
资金提存
推广和资讯
常见问题
联络我们
关于我们
交易细则
贵金属市场
交易平台
市场分析
推广和资讯
常见问题
联络我们
繁
简
EN
据国际文传电讯社:出口民调结果,执政党统一俄罗斯党预计在俄罗斯议会选举中获得49.4%的选票。
2026-09-21
据国际文传电讯社:出口民调结果,执政党统一俄罗斯党预计在俄罗斯议会选举中获得49.4%的选票。
返回
其他消息
2026-09-20
UBS expects global AI capital expenditure to approach $1.0 tln in 2026 and rise to about $1.4 tln in 2027, driven primarily by large memory price increases. UBS estimates memory-related spending will climb from $71 bln in 2025 to $367 bln this year and $923 bln in 2027. Other AI-related costs are forecast at $631 bln in 2026, falling to $525 bln in 2027. UBS says memory cost increases accounted for roughly 60% of this year’s AI capex uplift; by 2027, with other component spending declining, memo
UBS expects global AI capital expenditure to approach $1.0 tln in 2026 and rise to about $1.4 tln in 2027, driven primarily by large memory price increases. UBS estimates memory-related spending will climb from $71 bln in 2025 to $367 bln this year and $923 bln in 2027. Other AI-related costs are forecast at $631 bln in 2026, falling to $525 bln in 2027. UBS says memory cost increases accounted for roughly 60% of this year’s AI capex uplift; by 2027, with other component spending declining, memory’s rise could exceed the entire net increase in AI capex.
2026-09-20
Sept. 20 — National Medical Products Administration deputy director Yang Sheng said at a State Council Information Office briefing that during the 15th Five‑Year Plan period the NMPA will issue opinions to strengthen the drug safety responsibility framework, advance revisions to the Medical Device Administration Law and the Regulations on Protection of Traditional Chinese Medicine Varieties, and fully implement the Drug Administration Law implementing rules and supporting systems. The agency wil
Sept. 20 — National Medical Products Administration deputy director Yang Sheng said at a State Council Information Office briefing that during the 15th Five‑Year Plan period the NMPA will issue opinions to strengthen the drug safety responsibility framework, advance revisions to the Medical Device Administration Law and the Regulations on Protection of Traditional Chinese Medicine Varieties, and fully implement the Drug Administration Law implementing rules and supporting systems. The agency will roll out a drug and medical‑device standards upgrade plan, compile a 2030 edition of the Chinese Pharmacopoeia prioritizing essential medicines, drugs covered by medical insurance and high‑risk formulations, and step up standards research in frontier areas such as brain‑computer interfaces to drive quality improvements.
Chat with us
, powered by
LiveChat